Sandoz buys Aspen's Japanese generics business for up to $43...

Novartis’ biosimilars and generics division Sandoz has agreed to buy the Japanese business of the global generics firm Aspen in a deal worth up to 400 million euros ($434 million).

California is first US state to ban pay-for-delay deals

Pfizer confirms generic medicines merger with Mylan

Novartis secures initial block on Gilenya generics in US

Teva expands blood pressure drug recall in the US amid cance...

Teva has expanded a recall of losartan potassium tablets after tests revealed a potential human carcinogen in the blood pressure drug.

CEO of Novartis' generics unit quits, sparking sale speculat...

Richard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of March, sparking further speculation about the unit’s future.